IDH2 and acute myeloid leukemia: Whereas, GSCs metabolic plasticity represents a major challenge in the design of efficient therapies, tumor metabolic targeting holds great therapeutic potential in improving cancer treatment as shown by encouraging results observed using IDH mutant inhibitors in AML.